In Phase II Clinical Trials
Development of Effective and Innovative Medicines to Address the needs of Patients and Improve their Health, Longevity and Quality of Life.
Hub Controls
  • Demo Video
  • Upload Photo
  • Edit Company Profile
  • Add a Link
  • Update Fast Facts
  • Add Management Bios
  • Private Messages
  • Edit My Profile
  • View/Edit My Portfolio

Email Updates

AlphaRx > Message
Generic_profile

Re: NEWS - AlphaRx Reports Fiscal 2006 Year End Results

Posted by: drummer on January 04, 2007 04:18PM

In response to: NEWS - AlphaRx Reports Fisc... by AGORACOM

There are some solid numbers in the full year results section. Total revenues for the year ended September 30, 2006 were $1,024,774 as compared to $4,302 generated a year ago, an increase of $1,020,472. Royalty revenues from Indaflex sales in Mexico increased to $24,774 for the year ended September 30, 2006 as compared to $4,302 generated a year ago. Royalty revenues continue to increase based on increased sales of Indaflex in Mexico and their licensee considers that Indaflex is still in its launch phase.
Post a Reply

Please login to reply to this message.

Executive Address
Alrxsmall
Michael Lee
President
May 18, 2006

 

Michael Lee provides the investor community an update on recent events

View Broadcast

Stock Quote